China-South Asia Exp - SINOWAY on the Site

In order to implement the major decision of the Yunnan Provincial Committee of the CPC and People's Government of Yunnan Province to build a world-class "Healthy Living Destination", promote the development of the "whole industry chain" of the biomedicine and massive health industry in Yunnan province, integrate into the Belt and Road Initiative, and improve the international and social influence of Yunnan in related fields, the "Pavilion of Biomedicine and Massive Health" was unveiled at the South & Southeast Asia Commodity Expo and Investment Fair (SSACEIF) held from June 12 to 18, 2019.

As an invited biopharmaceutical enterprise, KunMing SINOWAY Natural Pharmaceuticals Co., Ltd. highlighted its core products "Periplaneta americana series products". Renowned as the "Kingdom of Plants" and the "Homeland of Medicinal Herbs", Yunnan province made the development of biomedical industry a priority to push the building of a world-class "Healthy Living Destination" and the development of biomedicine and massive health industry. Before that, SINOWAY had launched a series of superior products based on its deep exploration of "Periplaneta americana", contributing to the growth of the "Yunnan Medicine" brands and the development of products with high technological content and characteristics of Yunnan biomedicine.

Among the six product categories presented at the 2019 SSACEIF, KunMing SINOWAY highlighted two of them — Ganlong Capsule for the treatment of chronic hepatitis B (as an exclusive product, Ganlong Capsule is listed as a key ethnic medicine to be supported in the "Implementation Opinions of the General Office of the People's Government of Yunnan Province on Promoting the Healthy Development of Pharmaceutical Industry") and Kangfuxin Liquid for wound repair, both of which are made from Periplaneta americana.

In the future, KunMing SINOWAY will take Periplaneta americana series products represented by Kangfuxin Liquid and Ganlong Capsule as its medium and long-term strategic goals. KunMing SINOWAY has made significant progress in the research of active ingredients, function mechanism, active ingredient monomers and new indications of Periplaneta Americana by maintaining active communication and cooperation with first-class experts in related fields such as scientific research institutions and universities. Dozens of active monomers have been found and it has been confirmed through animal modal experiments that the active ingredients in Periplaneta americana are helpful to accelerate the healing of damaged cells and the growth of epidermal cells. KunMing SINOWAY will continue to increase relevant research and development efforts to fully promote the R&D of Periplaneta americana series products. That's how Periplaneta americana series products will continue to get new blood and grow bigger and stronger to become another biomedical product category of 10 billion sales in Yunnan province following Panax notoginseng and Erigeron breviscapus. 

Yunnan is taking great strides towards the goal of "making the people of Yunnan healthy and attracting health-desired people to come to Yunnan"! As the only company in China with the legal approval of using "Periplaneta americana" as an active pharmaceutical ingredient (API), KunMing SINOWAY Natural Pharmaceuticals Co., Ltd. will uphold the development concept of "Healthy City" of the provincial and municipal governments, take the protection of people's health as its mission, and vigorously develop a sustainable development goal strategy that integrates industries, universities, and research.